Bringing together resources from a number of major anti-infective congresses throughout 2012 and 2013, including ISICEM, EBMT, ECCMID, EHA, ESOT and TIMM; the Anti-infectives Knowledge Network shares the experience of a number of thought leaders.
Key transplantation reports and presentations from our 2013 coverage include:
... infectious disease physicians, transplant nephrologists, nurses, pharmacists, and other healthcare providers who are involved in the care of patients scheduled to undergo or who have undergone solid organ transplantation and are at risk for cytomegalovirus (CMV) infection.
The prevalence of renal acute rejection in transplantation is reduced thanks to the optimized use of immunosuppressive drugs. However, graft survival at ten years has not improved since then; this may be explained in part by the toxicity of these drugs, viral infections, and other comorbidities (diabetes,..
... cardiovascular diseases …).
According to transplant center, strategies for the combination of immunosuppressive drugs are different, and probably involve a difference in the global cost of patient management. There is no recommendation in France to establish similar practices.
EPHEGREN is an observational, prospective, multicentric, pharmacoeconomic study for the renal transplant patients.
The study is aiming to document the safety and effectiveness of renal denervation in patients after renal transplantation with hypertension. Catheter-based renal denervation will be performed using CE marked, percutaneous Symplicity catheter.